ImmunityBio (IBRX) Gross Margin (2023 - 2026)
ImmunityBio (IBRX) posted Gross Margin of 99.42% for Q2 2026, down 0.07 percentage points from 99.49% a year earlier and down 0.04 percentage points from the prior quarter.
Powered by 
Analysis
ImmunityBio (IBRX) Gross Margin (2023 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Gross Margin at ImmunityBio was 99.34%, down 0.32 percentage points year-over-year; for FY2025, it was 99.34%, down 0.66 percentage points from FY2024.
- Annual Gross Margin shows a three-year change of -0.66 percentage points (FY2022 to FY2025).
- In prior years, ImmunityBio's Gross Margin was 100.00% in FY2024 (unchanged), 100.00% in FY2023 (unchanged) and 100.00% in FY2022.
- Quarterly Gross Margin has run from a low of 99.00% in Q4 2025 to a high of 100.00% in Q4 2024 over five years.
- On a year-over-year basis, Gross Margin has declined in each of the last six quarters, with an average year-over-year change of -0.33 percentage points over the last eight quarters.
- Over the past five years, the year-over-year drop in Gross Margin ranged from 0.00 percentage points (Q4 2024) to 1.00 percentage points (Q4 2025).
- According to Business Quant data, Gross Margin for the three prior quarters was 99.46% (Q1 2026), 99.00% (Q4 2025) and 99.45% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 68.19% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 74.74% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 73.54% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 78.02% |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 83.60% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 72.04% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 79.76% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 72.78% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 85.33% |
| 10 | ImmunityBio | 8.97 Bn | 7.74 Bn | 50.94 Mn | 99.42% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 99.42% |
| Mar 31, 2026 | 99.46% |
| Dec 31, 2025 | 99.00% |
| Sep 30, 2025 | 99.45% |
| Jun 30, 2025 | 99.49% |
| Mar 31, 2025 | 99.65% |
| Dec 31, 2024 | 100.00% |
| Sep 30, 2024 | 100.00% |
| Jun 30, 2024 | 100.00% |
| Mar 31, 2024 | 100.00% |
| Dec 31, 2023 | 100.00% |
| Sep 30, 2023 | 100.00% |
| Jun 30, 2023 | 100.00% |
API Access
ImmunityBio Gross Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gross-margin&ticker=IBRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gross-margin", "ticker": "IBRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=gross-margin&ticker=IBRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();